TABLE 6.

Detection of HPV16 E7-reactive CD8⁺ T cells in patients with cervical cancer^a

Donor no.	PBL			TIL			Lymph node T cells			HPV16 status of tumor
	CD3+ CD8+ (%)	HPV (%)	CMV (%)	CD3+ CD8+ (%)	HPV (%)	CMV (%)	CD3+ CD8+ (%)	HPV (%)	CMV (%)
1	3.45	0.02	ND	14.7	0.00	ND	6.45	0.00	ND	+
2	14.2	0.02	0.06	52.4	0.01	0.02	ND	ND	ND	+
3	ND	ND	ND	13.7	0.02	0.01	ND	ND	ND	+
4	16.7	0.04	1.00	ND	ND	ND	ND	ND	ND	+
5	6.74	0.02	ND	ND	ND	ND	ND	ND	ND	+
6	23.2	0.00	0.10	46.4	0.00	0.03	4.28	0.00	0.01	+
7	15.1	0.06	0.72	ND	ND	ND	ND	ND	ND	+
8	17.6	0.02	0.03	14.8	0.02	ND	ND	ND	ND	+
9	ND	ND	ND	8.57	0.00	0.02	ND	ND	ND	+
10	ND	ND	ND	14.4	0.00	ND	ND	ND	ND	−
11	18.6	0.00	0.00	ND	ND	ND	ND	ND	ND	+
12	22.2	0.03	ND	ND	ND	ND	ND	ND	ND	+
13	9.57	0.47	0.30	26.6	0.02	0.01	24.7	0.04	0.01	+
14	38.1	0.18	0.69	ND	ND	ND	ND	ND	ND	+
15	15.1	0.01	0.26	20.0	0.04	0.37	ND	ND	ND	+
16	14.2	0.00	0.00	15.7	0.03	ND	ND	ND	ND	+
17	17.1	0.00	0.02	9.02	0.01	0.00	8.91	0.00	0.01	−
18	15	1.6	1.7	43.5	0.08	0.00	19.81	0.03	0.4	+

^aSee footnotes to Table 5 for details.